Bristol To Devote $125 Mil. To Develop Medarex' Metastatic Melanoma Agent
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol adds Phase III anti-CTLA-4 product MDX-010 to its franchise as several of its oncologics are exposed to generic competition. Medarex cites upside potential as a reason for entering into the collaboration with Bristol.
You may also be interested in...
Bristol-Myers Squibb And Medarex To Refile Oncology Agreement With FTC
The Federal Trade Commission requests additional information related to Bristol's $192 mil. development agreement for Medarex' metastatic melanoma agent. The extended review period is expected to expire in January.
Bristol-Myers Squibb And Medarex To Refile Oncology Agreement With FTC
The Federal Trade Commission requests additional information related to Bristol's $192 mil. development agreement for Medarex' metastatic melanoma agent. The extended review period is expected to expire in January.
Abatacept Launch Will Be Bolstered By Unmet Need In RA Market – Bristol
Bristol is focusing on rheumatoid arthritis patients who do not respond to TNF inhibitors. The initial launch material will come from Bristol's Syracuse, N.Y. facility; the company will rely on contract manufacturer Lonza to provide additional supply once a supplemental BLA is approved.